The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Topic: Drugs - Primary Care

Monday, 21 November 2016
Many patients with heart failure rely on practice nurses to monitor their care. A multidisciplinary team (MDT) integrated community approach has been endorsed by NICE guidelines when delivering HF care. This article provides practice nurses with the information they need to understand the condition, current treatment guidelines, and the new treatment – sacubitril/valsartan, the first-in-class angiotensin receptor-neprilysin inhibitor.
Category: Editorial
Thursday, 24 November 2016
The large randomised controlled trial PARADIGM-HF showed that treatment with sacubitril/valsartan (Entresto) compared with enalapril reduced the risk of hospitalisation, cardiovascular and all-cause mortality and improved symptoms in patients with heart failure with reduced ejection fraction. This article describes the key results and how they can be applied in primary care.
Category: Editorial
Monday, 21 November 2016
This article describes the use of sacubitril/valsartan – the first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) in primary care and how the new drug fits in the heart failure treatment pathway. Current guidelines and case studies are also explored to provide further understanding of this latest HF treatment to enter clinical use.
Category: Editorial
Monday, 21 November 2016
This article gives an overview of sacubitril/valsartan (Entresto), a first-in-class angiotensin receptor-neprilysin inhibitor comprising valsartan, an angiotensin II receptor blocker and the neprilysin inhibitor sacubitril. The drug has been approved for the treatment of symptomatic (NYHA class (II-IV) chronic heart failure and reduced ejection fraction (HF-REF) in adults.
Category: Editorial
Thursday, 01 October 2020
The first of 3 interactive programmes providing practical answers about the use of insulin. Jane Diggle and Hannah Beba help to 'demystify' insulin in primary care - what's stopping us and what do we need to know?
Category: Webinars
Tuesday, 13 October 2020
The second of 3 interactive programmes providing practical answers about the use of insulin. Nicola Milne and Su Down take a look at how we can make the most of insulin - How to initiate and how and when to titrate?
Category: Webinars
Tuesday, 27 October 2020
The last of our 3 interactive programmes providing practical answers about the use of insulin. Jane Diggle and Su Down discuss the main dangers associated with insulin how we can ensure its safe use within primary care.
Category: Webinars
Monday, 21 November 2016
This useful Back to Basics poster describes the damaging changes that take place in three key body systems when HF with reduced ejection fraction is left untreated. The sympathetic nervous system, the renin-angiotensin-aldosterone system and the natriuretic peptide system all undergo significant pathophysiological changes as HF progresses.
Category: Back to Basics
Monday, 21 November 2016
The mechanisms underlying HF are complex and involve the interaction of many hormonal and molecular signalling pathways. These pathways form the basis of many pharmacological treatments, old and new. This article will examine the factors associated with the development of HF, the pathophysiology behind it and the neurohormonal pathways involved in established HF.
Category: Editorial
Page 3 of 3

Article search and filter